Cirmtuzumab, a ROR1 monoclonal antibody is finally here in a Phase 1 clinical trial at UCSD after years of promise. The hope is that it will be as effective and targeted in real patients as it has been in the lab. Its promise is that it will just massively kill the CLL clone and spare the normal B cells unlike the CD20 mAb, whatever generation. That would be a real bonus, but it is a Phase 1 trial.
On my blog (http://bkoffman.blogspot.com ), I review the back story of ROR1with a video interview with Dr. Kipps and discuss more about the ethical design of Phase 1 trials.